Stacy Mandras, MD
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1407069818
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. United Therapeutics Corporation accounts for 64.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $27,311 and has fallen 91.1% since, to $2,424 in 2025.
Across 239 payments — averaging $416.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$64K
- Bayer$20K
- Cvrx, Inc.$10K
- Abbott$2K
- Abiomed$800
- Actelion Pharmaceuticals US, Inc.$792
- plus $2K from 18 others
Across 75 payments — averaging $11,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$538K
- United Therapeutics Corporation$108K
- Janssen Research & Development, LLC$75K
- Actelion Pharmaceuticals, Ltd$63K
- Bayer$59K
- Insmed, Inc.$16K
What the payments were for
- Consulting fees$33,82334%
- Speaking & faculty fees$48,91049%
- Travel & lodging$5,9376%
- Food & beverage$10,86811%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 93 | $64,423 |
| Bayer | 27 | $20,366 |
| Cvrx, Inc. | 39 | $9,988 |
| Abbott | 25 | $1,666 |
| Abiomed | 7 | $800 |
| Actelion Pharmaceuticals US, Inc. | 14 | $792 |
| Merck | 9 | $456 |
| Impulse Dynamics (USA) Inc. | 2 | $194 |
| Daxor Corporation | 2 | $145 |
| Medtronic | 2 | $131 |
| La Jolla Pharmaceutical Company | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $83 |
| Sandoz | 1 | $70 |
| Johnson & Johnson | 4 | $58 |
| Nuwellis, Inc. | 1 | $32 |
| Edwards Lifesciences | 1 | $29 |
| American Regent | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Briohealth Solutions, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Pfizer | 1 | $18 |
| Gilead | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REMODULIN$21,584
- Adempas$19,885
- TYVASO$16,630
- NONE$13,032
- Barostim Neo System$9,198
- ORENITRAM$7,754
- Impella$564
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$545
- OPTIMIZER$347
- CardioMEMS HF System$347
- UPTRAVI$254
- HeartMate 3 Left Ventricular Dev$149
- OPSUMIT$145
- HeartMate$127
- Xerava$124
- LIVTENCITY$122
- BVA-100$120
- HeartWare HVAD$119
How this compares
$99,617 in reported general payments places this provider in the 80th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 92 | $2,122,066 |
| AdempasRiociguat | 102 | $1,404,613 |
| UptraviSelexipag | 34 | $909,104 |
| OpsumitMacitentan | 69 | $853,274 |
| Orenitram ErTreprostinil Diolamine | 15 | $313,030 |
| Ambrisentan | 49 | $222,182 |
| WinrevairSotatercept-Csrk | 13 | $184,342 |
| Tadalafil | 52 | $68,325 |
| EntrestoSacubitril/Valsartan | 17 | $25,568 |
| JardianceEmpagliflozin | 30 | $22,664 |
| Sildenafil Citrate | 31 | $8,338 |
| Tacrolimus | 27 | $7,780 |
| EliquisApixaban | 13 | $7,408 |
| Mycophenolate Mofetil | 18 | $1,150 |
| Bumetanide | 17 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $792 | $1,762,378103 claims |
| BayerAdempas | $20,366 | $1,404,613102 claims |
| MerckWinrevair | $456 | $184,34213 claims |
| NovartisEntresto | $15 | $25,56817 claims |
| PfizerEliquis | $18 | $7,40813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Naveen BellamOrlando$414K
- Pujan PatelOrlando$66K
- Andrija VidicOrlando$18K
- Shahid QamarOrlando$9K
- Jacqueline DoweOrlando$7K
- Sushma KoneruOrlando$7K
- Mauricio VelezOrlando$6K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.